Evidence map›Paper›PMID 38420210›Full record

ArticleFrontiers in veterinary science2024

Evaluation of stability and safety of equine mesenchymal stem cells derived from amniotic fluid for clinical application.

Eun Young Kim, Eun Ji Lee, Ryoung Eun Kim, Tae Young Kil, Min Kyu Kim

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Eun Young Kim *MK Biotech Co., Ltd., Daejeon, Republic of Korea.
Eun Ji Lee *Division of Animal and Dairy Science, College of Agriculture and Life Science, Chungnam National University, Daejeon, Republic of Korea.
Ryoung Eun KimMK Biotech Co., Ltd., Daejeon, Republic of Korea.
Tae Young KilDepartment of Social Welfare, Joongbu University, Chungcheongnam-do, Republic of Korea.
Min Kyu KimMK Biotech Co., Ltd., Daejeon, Republic of Korea.
STR Biotech (South Korea) · KRChungnam National University · KRJoongbu University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amniotic fluid mesenchymal stem cells (AF-MSCs), which can be obtained from fetal tissue, reportedly have self-renewal capacity and multi-lineage differentiation potential. The aim of this study was to identify the biological characteristics of AF-MSCs and evaluate their stability and safety in long-term culture. To confirm the biological characteristics of AF-MSCs, morphology, proliferation capacity, karyotype, differentiation capacity, gene expression level, and immunophenotype were analyzed after isolating AF-MSCs from equine amniotic fluid. AF-MSCs were differentiated into adipocytes, chondrocytes, and osteocytes. Immunophenotype analyses revealed expression levels of ≥95% and ≤ 2% of cells for a positive and negative marker, respectively. Analysis of the MSCs relative gene expression levels of AF-MSCs was approximately at least twice that of the control. The endotoxin level was measured to verify the safety of AF-MSCs and was found to be less than the standard value of 0.5 EU/ml. AF-MSCs were cultured for a long time without any evidence of abnormalities in morphology, proliferation ability, and karyotype. These results suggest that amniotic fluid is a competent source for acquiring equine MSCs and that it is valuable as a cell therapy due to its high stability.

Indexed as

amniotic fluidequine (horse)long-term culturemesenchymal stem cellsstability and safety for cell therapy

Identifiers

PMID38420210
PMCPMC10899390
OpenAlexW4391818619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.